Thanks for joining DividendStocks.com, the daily newsletter built for dividend and income investors like you. We’re thrilled to have you on board and can’t wait to help you discover the best dividend opportunities out there. Before we can start sending your daily insights, please take a quick moment to confirm your subscription: Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Why wait? Let’s get your dividend journey started! Click Here to Start Discovering Top Income-Generating Stocks See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Featured Content from MarketBeat 2 Small-Cap Biotechs That Could Reward Patient InvestorsWritten by Chris Markoch. Published 12/12/2025. 
Key Points - Small-cap biotech stocks like Mainz Biomed and NanoViricides offer high risk but the potential for outsized returns as their diagnostic and antiviral pipelines advance.
- Mainz Biomed’s ColoAlert test provides early commercial traction, but limited revenue and ongoing cash needs continue to pressure MYNZ stock.
- NanoViricides’ nanomedicine antiviral platform shows promising preclinical data, yet NNVC remains a speculative bet dependent on new funding and pipeline progress.
Speculative investing and patience rarely go together. Nevertheless, if you’re looking to invest in the small-cap biotech sector, patience is essential. Most of these companies remain in the clinical stage, meaning they have no commercially available drugs or therapeutics. That also means negative earnings (i.e., they are not profitable) and little to no revenue. Success often hinges on the outcome of a single clinical program. A tiny government task force just wrapped up 20 years of work.
And buried in their federal filings, I found something remarkable:
American citizens now have a legal birthright claim to something previously inaccessible.
Under U.S. law, you can stake your claim right now. The name and ticker are available here now >>> Even when a product advances through trials, profitability may still be years away. Only after that milestone do companies attract analyst coverage and institutional investment. However, getting in on one of these medical stocks and having it succeed can produce dramatic returns. Investors who hit on the right company could see 3x, 5x, or even 10x gains. Others may never pan out. That is why many investors interested in penny stocks spread capital across multiple biotech names — if it’s a numbers game, diversification can be an effective strategy. With that in mind, let’s look at two small-cap biotech stocks that carry significant risks but also the potential for outsized returns. Mainz Biomed: Early Cancer Detection With High Upside Potential Mainz Biomed AG (NASDAQ: MYNZ) is a German molecular diagnostics company focused on epigenetics-based tests for early cancer detection. Unlike many penny stocks, Mainz Biomed already markets a product: ColoAlert–the first DNA-based screening test for colorectal cancer in Europe. On Dec. 2, Mainz Biomed announced that ColoAlert was added to the portfolio of DoctorBox, a leading German digital-health pioneer. With more than 60,000 new colorectal cancer cases annually in Germany, the market opportunity is meaningful. Mainz Biomed is also developing a non-invasive, blood-based screening test for early detection of pancreatic cancer. The company reported positive topline results in October, but commercial approval is still years away. Risks are substantial. ColoAlert is not yet available in the United States, and despite early sales in Europe and plans to expand into South America, revenue remains minimal. That is why the company included “going concern” language in its Sept. 26 SEC filing. Since then, Mainz Biomed has filed a $150 million mixed shelf offering, which for now helps keep MYNZ above $1 and avoids a delisting notice. The company must begin generating meaningful revenue to change the narrative. If it succeeds, even a relatively small position could produce a sizable return. NanoViricides: High-Risk Antiviral Play With Breakthrough Potential NanoViricides Inc. (NYSE: NNVC) is another micro-cap biotech pursuing a potentially disruptive approach to antiviral therapy, but it carries the financial risks speculative investors must weigh carefully. The company is developing a novel class of antiviral therapies based on its proprietary “nanoviricide” platform. These candidates are designed to mimic human cell surfaces, luring viruses into binding with them and neutralizing the pathogens before they can infect real cells. It’s an innovative concept that, if validated in human trials, could represent a new approach to infectious-disease treatment. NanoViricides’ pipeline includes candidates targeting shingles (varicella-zoster virus), HSV-1 and HSV-2, and broad-spectrum influenza. Its shingles program, NV-HSC, is the most advanced and has shown encouraging preclinical antiviral activity. Like many micro-cap biotechs, NanoViricides remains pre-revenue and dependent on fresh capital to continue development. The company has reported limited cash on hand in recent filings, so investors should expect the possibility of future dilution. Still, if even one candidate advances successfully into clinical development, the valuation upside could be substantial. For investors with patience and a high tolerance for risk, NNVC represents a genuine moonshot in the antiviral space.
| 
